2025
Jeong, D. I., Hao, Q., Lee, S. Y., Kim, S., Karmakar, M., Chu, S., Park, M., & Cho, H. J. (2025). Cellulose nanocrystal-annealed hydrogel system for local chemo-metabolic therapy of melanoma. J Control Release, 377, 324-338. https://doi.org/10.1016/j.jconrel.2024.11.015 (IF: 11.5)
Choi, Y. J., Kim, M. J., Lee, Y. J., Choi, M., Shim, W. S., Park, M., Kim, Y. C., & Kang, K. W. (2025). Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK inhibitors. Theranostics, 15(3), 875-893. https://doi.org/10.7150/thno.100970 (IF: 13.3)
2024
Choi, Y. J., Choi, M., Park, J., Park, M., Kim, M. J., Lee, J. S., Oh, S. J., Lee, Y. J., Shim, W. S., Kim, J. W., Kim, M. J., Kim, Y. C., & Kang, K. W. (2024). Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer. Biomed Pharmacother, 171, 116124. https://doi.org/10.1016/j.biopha.2024.116124 (IF: 7.5)
Lee, J. E., Kim, M., Ochiai, S., Kim, S. H., Yeo, H., Bok, J., Kim, J., Park, M., Kim, D., Lamiable, O., Lee, M., Kim, M. J., Kim, H. Y., Ronchese, F., Kwon, S. W., Lee, H., Kim, T. G., & Chung, Y. (2024). Tonic type 2 immunity is a critical tissue checkpoint controlling autoimmunity in the skin. Cell Rep, 43(7), 114364. https://doi.org/10.1016/j.celrep.2024.114364 (IF: 6.9)
Park, J., Purushothaman, B., Hong, S., Choi, M., Jegal, K. H., Park, M., Song, J. M., & Kang, K. W. (2024). GRP78 blockade overcomes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer. Life Sci, 348, 122681. https://doi.org/10.1016/j.lfs.2024.122681 (IF: 5.1)
2023
Park, M.*, Kuen, D. S., Park, J., Choi, M., Kim, Y., Roh, E. C., Choi, Y. J., Kim, Y. G., Chung, Y., Cho, S. Y., & Kang, K. W. (2023). TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment. J Immunother Cancer, 11(1). https://doi.org/10.1136/jitc-2022-006084 (IF:10.6, immunology 6.3%)
Park, M.*, Kang, K. W., & Kim, J. W. (2023). The role and application of transcriptional repressors in cancer treatment. Arch Pharm Res, 46(1), 1-17. https://doi.org/10.1007/s12272-023-01427-4 (IF:7.5, Pharmacology and pharmacy 5.3%)
Kim, S. J., Lee, K., Park, J., Park, M., Kim, U. J., Kim, S. M., Ryu, K. H., & Kang, K. W. (2023). CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer. Toxicol Res, 39(1), 61-69. https://doi.org/10.1007/s43188-022-00146-0
Choi, Y. J., Park, J., Choi, H., Oh, S. J., Park, J. H., Park, M., Kim, J. W., Kim, Y. G., Kim, Y. C., Kim, M. J., & Kang, K. W. (2023). PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia. Biomed Pharmacother, 165, 115066. https://doi.org/10.1016/j.biopha.2023.115066
2022
Park, M.*, Lee, S. H.*, Bui, Q. T., Kim, Y. M., & Kang, K. W. (2022). The essential role of YAP in ERalpha36-mediated proliferation and the epithelial-mesenchymal transition in MCF-7 breast cancer cells. Front Pharmacol, 13, 1057276. https://doi.org/10.3389/fphar.2022.1057276 (IF:4.8, PHARMACOLOGY & PHARMACY 14.3%)
Lee, Y. J., Park, M., Kim, H. Y., Kim, J. K., Kim, W. K., Lim, S. C., & Kang, K. W. (2022). Circulating small extracellular vesicles promote proliferation and migration of vascular smooth muscle cells via AXL and MerTK activation. Acta Pharmacol Sin. https://doi.org/10.1038/s41401-022-01029-8
2021
Park, M.*, Kim, J. W., Kim, K. M., Kang, S., Kim, W., Kim, J. K., Cho, Y., Lee, H., Baek, M. C., Bae, J. H., Lee, S. H., Jeong, S. B., Lim, S. C., Jun, D. W., Cho, S. Y., Kim, Y., Choi, Y. J., & Kang, K. W. (2021). Circulating Small Extracellular Vesicles Activate TYRO3 to Drive Cancer Metastasis and Chemoresistance. Cancer Res, 81(13), 3539-3553. https://doi.org/10.1158/0008-5472.CAN-20-3320 (IF:16.6, Oncology, 4.8%)
Kuen, D. S., Park, M., Ryu, H., Choi, G., Moon, Y. H., Kim, J. O., Kang, K. W., Kim, S. G., & Chung, Y. (2021). Critical regulation of follicular helper T cell differentiation and function by Galpha(13) signaling. PNAS, 118(43). https://doi.org/10.1073/pnas.2108376118 (IF: 9.1)
Kim, J. W., Park, M., Kim, S., Lim, S. C., Kim, H. S., & Kang, K. W. (2021). Anti-metastatic effect of GV1001 on prostate cancer cells; roles of GnRHR-mediated Galphas-cAMP pathway and AR-YAP1 axis. Cell Biosci, 11(1), 191. https://doi.org/10.1186/s13578-021-00704-3 (IF:6.2)
2019
Park, M.*, Kim, J.*, Phuong, N. T. T., Park, J. G., Park, J. H., Kim, Y. C., Baek, M. C., Lim, S. C., & Kang, K. W. (2019). Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production. Sci Rep, 9(1), 11587. https://doi.org/10.1038/s41598-019-47734-z (IF:3.9, Citation:57)
Park, M.*, & Kang, K. W. (2019). Phosphatidylserine receptor-targeting therapies for the treatment of cancer. Arch Pharm Res, 42(7), 617-628. https://doi.org/10.1007/s12272-019-01167-4 (IF:7.5, Pharmacology and pharmacy 5.3%)